GSK plc
GSK, GLAXF · Pharmaceutical Preparations · EDGAR filings ↗
Reference price $19.00 — last insider purchase, 2025-12-11 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
A87Dominant, scaled global pharma franchise with top-decile returns, margins, and cash generation.
Strengths
- Top-decile ROIC (96th pct), ROA (92nd), operating margin (92nd) and FCF (98th)
- High ROE ~39% (86th pct) and strong net income growth (89th pct) with deep R&D pipeline
Risks
- Weak current/quick ratios (~13th/12th pct) and leverage (82nd pct)
- Pipeline-delivery, product-quality and legal/compliance risks flagged in the filing
Notable findings
- Weak liquidityCurrent ratio 0.82 (<1)
- Strong balance sheetStrong balance sheet — $4.6B cash & investments
- China exposureContext The general landscape for anti-bribery and corruption, outgoing fraud, competitive practices, and sanctions and export controls continues to be c
- Notable holderHeld by 6 notable fund(s): FMR LLC, GOLDMAN SACHS GROUP INC, STATE STREET CORP +3 more (as of 2026-03-31)
Key metrics
Gross margin
72.4%
Operating margin
24.3%
Net margin
19.3%
Return on equity
39.4%
Return on assets
10.3%
ROIC
20.6%
Revenue growth (QoQ)
11.7%
Net-income growth
128.6%
Debt / equity
0.9×
Interest coverage
11.3×
Current ratio
0.8×
Free cash flow
$8.6B
Tangible book value
$12.0B
Cash & investments
$4.6B
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-12-11 | GSK plc | Buy | 1.5M | $19.00 |
All non-derivative Form 4 activity (SEC), newest first.
Supply chain
Customers (0)
Named in the 10-K; linked when we track them.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-06 | 2025-12-31 | 0001131399-26-000004 ↗ |
| 20-F | 2025-03-03 | 2024-12-31 | 0001131399-25-000007 ↗ |
| 20-F | 2024-03-05 | 2023-12-31 | 0001131399-24-000007 ↗ |
| 20-F | 2023-03-10 | 2022-12-31 | 0001193125-23-067105 ↗ |